This is read by an automated voice. Please report any issues or inconsistencies here. Five hikers huddled in a tent designed for three during a ferocious lightning storm near Mount Whitney’s ...

A recruiter involved in enlisting young Sudanese men to fight in the Russian army told Ayin that only 15% of those recruited by Russia are actually fighting in Ukraine. Another recruiter, speaking ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...

Join Luke Nichols from OutdoorBoys as he ventures deep into the Alaskan interior, spending a night in a snowstorm without a tent or sleeping bag. He builds a fire-heated shelter from scratch, gathers ...

A guest lecture by Tikhon Dzyadko, a prominent Russian journalist, television presenter, and media manager. Dzyadko previously worked at radio station Echo of Moscow, and he is currently ...

As a second Ukraine summit between President Donald Trump and Russian President Vladimir Putin is called off and the war drags on, Oct. 24 will mark United Nations Day, commemorating the entry into ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Vladimir Putin has staked the fate of his presidency, and Russian imperial ambitions, on the outcome of the war in Ukraine. Russia’s war on Ukraine was never really about NATO expansion or Western ...

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...